Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure

04 Aug 2020 08:00 CEST

Company Name

BIOPHYTIS

ISN

FR0012816825

Market

Euronext Growth

Symbol

ALBPS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_939501_Biophytis__COVA_Brazil_approval__PR_EN_Fv.pdf

Source

BIOPHYTIS

Provider

Les Echos

Attachments

  • Original document
  • Permalink

Disclaimer

Biophytis SA published this content on 04 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2020 07:11:09 UTC